COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,889 Articles (22,568 medRxiv, 8,321 bioRxiv)

Most recent first Previous |  Page 1674: Articles 16731-16740  | Next

Shed the light on virus: virucidal effects of 405 nm visible light on SARS-CoV-2 and influenza A virus.
Yahnke, C. J., Rathnasinghe, R. J., Garcia-Sastre, A.
10.1101/2021.03.14.435337 — Posted: 2021-03-15
Antibody evasion by the Brazilian P.1 strain of SARS-CoV-2
Dejnirattisai, W., Zhou, D., Supasa, P., Liu, C., Mentzer, A. J., Ginn, H., Zhao, Y., Duyvesteyn, H. M. E., Tuekprakhon, A., Nutalai, R., Wang, B., Paesen, G. C., Lopez-Camacho, C., Slon-Campos, J., Walter, T., Skelly, D., Clemens, S. A. C., Naveca, F. G., Nascimento, V., Nascimento, F., da Costa, C. F., Dold, C., Levin, R., Dong, T., Pollard, A. J., Knight, J. C., Crook, D., Lambe, T., Clutterbuck, E., Bibi, S., Flaxman, A., Bittaye, M., Belij-Rammerstorfer, S., Gilbert, S., Carroll, M. W., Klenerman, P., Barnes, E., Dunachie, S. J., Paterson, N. G., Williams, M. A., Hall, D. R., Hulswit, R., Bowden, T. A., Fry, E. E., Mongkolsapaya, J., Ren, J., Stuart, D. I., Screaton, G. R.
10.1101/2021.03.12.435194 — Posted: 2021-03-15
BNT162b2 mRNA COVID-19 vaccine induces antibodies of broader cross-reactivity than natural infection but recognition of mutant viruses is up to 10-fold reduced
Mohsen, M., Bachmann, M. F., Vogel, M., Augusto, G. S., Liu, X., Chang, X.
10.1101/2021.03.13.435222 — Posted: 2021-03-15
Effects of Mutations in the Receptor-Binding Domain of SARS-CoV-2 Spike on its Binding Affinity to ACE2 and Neutralizing Antibodies Revealed by Computational Analysis
Bozdaganyan, M. E., Sokolova, O. S., Shaitan, K. V., Kirpichnikov, M. P., Orekhov, P. S.
10.1101/2021.03.14.435322 — Posted: 2021-03-15
One-shot identification of SARS-CoV-2 S RBD escape mutants using yeast screening
Francino Urdaniz, I., Steiner, P. J., Kirby, M., Zhao, F., Haas, C. M., Barman, S., Rhodes, E. R., Peng, L., Sprenger, K., Jardine, J., Whitehead, T. A.
10.1101/2021.03.15.435309 — Posted: 2021-03-15
S-acylation controls SARS-Cov-2 membrane lipid organization and enhances infectivity
Mesquita, F. S., Abrami, L., Sergeeva, O., Turelli, P., Kunz, B., Raclot, C., Paz Montoya, J., Abriata, L., Dal Peraro, M., Trono, D., D'Angelo, G., van der Goot, F. G.
10.1101/2021.03.14.435299 — Posted: 2021-03-15
Structure, Mechanism and Crystallographic fragment screening of the SARS-CoV-2 NSP13 helicase
Newman, J. A., Douangamath, A., Yazdani, S., Yosaatmadja, Y., Aimon, A., Brandao-Neto, J., Dunnett, L., Gorrie-Stone, T., Skyner, R., Fearon, D., Schapira, M., von Delft, F., Gileadi, O.
10.1101/2021.03.15.435326 — Posted: 2021-03-15
Differential gene expression by RNA-Seq in Sigma-2 Receptor/TMEM97 knockout cells reveals its role in complement activation and SARS-CoV-2 viral uptake
Riad, A., Aubert, Y., Zeng, C., Graham, T. J. A., Petersson, E. J., Capell, B. C., Mach, R. H.
10.1101/2021.03.14.435180 — Posted: 2021-03-15
A map of direct SARS-CoV-2 protein interactions implicates specific human host processes
Kim, D.-K., Weller, B., Lin, C.-W., Sheykhkarimli, D., Knapp, J. J., Kishore, N., Sauer, M., Rayhan, A., Young, V., Marin-de la Rosa, N., Pogoutse, O., Spirohn, K., Strobel, A., Laval, F., Schwehn, P., Li, R., Simin, R., Altmann, M., Cassonnet, P., Dugied, G., Cote, A. G., Elorduy Vergara, L., Hazelwood, I., Liu, B. B., Nguyen, M., Pandiarajan, R., Rodriguez Coloma, P. A., Willems, L., Twizere, J.-C., Demeret, C., Jacob, Y., Hao, T., Hill, D. E., Falter, C., Vidal, M., Calderwood, M. A., Roth, F. P., Falter-Braun, P.
10.1101/2021.03.15.433877 — Posted: 2021-03-15
A novel soluble ACE2 protein totally protects from lethal disease caused by SARS-CoV-2 infection
Hassler, L., Wysocki, J., Gelarden, I., Tomatsidou, A., Nicoleascu, V., Randall, G., Henkin, J., Yeldandi, A., Batlle, D.
10.1101/2021.03.12.435191 — Posted: 2021-03-15

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).